Mental illness doesn't exist in a vacuum – it impacts those who suffer and the people around them. One in four people will be affected by mental illness at some point in their lives, and those caring for someone with mental illness will experience anxiety or depression at a higher rate.
Our team's ambition is to improve the lives of those suffering from mental illness by changing the expectation of treatment. Today's treatment options focus on managing symptoms, versus healing the underlying condition, often with unpleasant side effects and low rates of success.
Psychedelic therapies offer a novel approach to mental healthcare, focused on treating the underlying conditions and improving the patient experience and outcome. A paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens.
Cybin (NEO:CYBN) (OTCQB:CLXPF) is at the forefront of this revolution. We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. While psychedelics may represent a new industry, we recognize the long history of use within indigenous cultures and major scientific breakthroughs over the decades that have led us to where we are today.
An experienced Corporate Director and CEO: Doug has chaired the Board of a NASDAQ-listed company and, as CEO for the past 13 years, has built and turned-around 4 pharmaceutical companies. During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents and has raised $4 billion of both public and private capital.
In 2008, Doug led the turnaround of Norwich Pharmaceuticals and became the Founding CEO of parent company, Alvogen. During his 5.5-year tenure as CEO, Doug transformed Norwich’s manufacturing, adding extensive R&D capabilities. At the same time, Alvogen grew from inception to $450 million in revenues across 35 countries, building an R&D facility in NJ, a Contract Research Organization in India, and creating a product development pipeline of over 50 products for the US market.
In early 2014, Doug led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising $65 million. Within the first year of taking the helm as Chairman and CEO, Doug rebuilt the management team and BOD, combined several operating locations, divested loss-making manufacturing, built a 220-person sales team, with supporting functions (sales training, sales operations, marketing) growing the company’s enterprise value from $80 million to around $800 million. Under Doug’s leadership, Pernix raised $465 million of capital.
From late 2017 to mid-2020, Doug was Director and CEO of Tedor Pharma, a contract manufacturing business. Doug’s efforts to turnaround the business resulted in 60% revenue growth in 2019, leading to Tedor being recognized as one of America’s fastest-growing companies, making it to the 2020 Inc 5000 list.
Previously, Doug was Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including over 25 banks, to fund the company’s growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.
Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012. Doug is an enthusiastic traveler, having traveled to over 45 countries, is an avid reader, and enjoys cooking and boating.